​

Ligand Pharmaceuticals (LGND) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LGND Stock Forecast

Ligand Pharmaceuticals (LGND) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $146.00, with a high of $157.00 and a low of $135.00. This represents a 22.77% increase from the last price of $118.92.

$65 $84 $103 $122 $141 $160 High: $157 Avg: $146 Low: $135 Last Closed Price: $118.92

LGND Stock Rating

Ligand Pharmaceuticals stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

LGND Forecast vs Benchmarks

TypeNameUpside
StockLigand Pharmaceuticals22.77%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$141.20
Last Closing Price$118.92$118.92$118.92
Upside/Downside--18.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2543---7
Dec, 2443---7
Nov, 24441--9
Oct, 24461--11
Sep, 24461--11
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024Joseph PantginisH.C. Wainwright$157.00$108.3144.95%32.02%
Oct 02, 2024Leland GershellOppenheimer$135.00$99.9535.07%13.52%
Jul 30, 2024Douglas MiehmRBC Capital$130.00$108.7519.54%9.32%
Jul 09, 2024Matt HewittCraig-Hallum$140.00$86.8861.14%17.73%
Jun 28, 2024Joseph PantginisH.C. Wainwright$144.00$82.3374.91%21.09%
Dec 23, 2022Roth Capital$90.00$67.3233.69%-24.32%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 18, 2024H.C. WainwrightBuyBuyhold
Oct 03, 2024RBC CapitalBuyBuyhold
Oct 02, 2024OppenheimerOutperforminitialise
Aug 12, 2024BenchmarkBuyBuyhold
Jul 30, 2024RBC CapitalBuyBuyhold
Jul 30, 2024RBC CapitalOutperforminitialise
Jul 09, 2024Craig-HallumBuyBuyhold
Jun 28, 2024H.C. WainwrightBuyBuyhold
Dec 23, 2022Roth CapitalBuyBuyhold
Jul 05, 2022BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$-1 $1 $3 $5 $7 $9 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.18$3.44$-0.31$2.94-----
Avg Forecast$2.53$3.87$2.79$5.35$5.66$6.07$6.78$7.72$8.54
High Forecast$2.35$3.59$2.64$4.97$3.47$4.97$6.40$7.17$7.93
Low Forecast$2.79$4.25$2.85$5.47$6.80$7.57$7.17$7.90$8.74
Surprise %-107.11%-11.11%-111.11%-45.05%-----

Revenue Forecast

$100M $150M $200M $250M $300M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$186.42M$277.13M$196.25M$131.31M-----
Avg Forecast$173.06M$269.76M$203.95M$128.89M$163.37M$187.13M$225.03M$262.60M$302.00M
High Forecast$163.73M$255.22M$195.53M$128.58M$162.49M$186.43M$223.45M$261.28M$285.48M
Low Forecast$186.47M$290.66M$207.04M$129.19M$163.82M$187.65M$226.62M$263.92M$307.38M
Surprise %7.72%2.73%-3.78%1.88%-----

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.98M$57.14M$-5.22M$52.15M-----
Avg Forecast$-1.78M$51.75M$26.46M$53.82M$91.14M$111.34M$120.52M$133.80M$151.64M
High Forecast$-10.23M$40.17M$12.92M$22.12M$61.53M$88.26M$113.64M$127.34M$140.86M
Low Forecast$6.67M$63.33M$40.01M$85.52M$120.75M$134.42M$127.40M$140.26M$155.16M
Surprise %67.69%10.42%-119.72%-3.09%-----

LGND Forecast FAQ

Is Ligand Pharmaceuticals stock a buy?

Ligand Pharmaceuticals stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ligand Pharmaceuticals is a favorable investment for most analysts.

What is Ligand Pharmaceuticals's price target?

Ligand Pharmaceuticals's price target, set by 6 Wall Street analysts, averages $146 over the next 12 months. The price target range spans from $135 at the low end to $157 at the high end, suggesting a potential 22.77% change from the previous close price of $118.92.

How does Ligand Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Ligand Pharmaceuticals stock forecast shows a 22.77% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Ligand Pharmaceuticals over the past three months?

  • January 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 44.44% Strong Buy, 44.44% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Ligand Pharmaceuticals’s EPS forecast?

Ligand Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is 5.66 for 2024, a 92.52% increase from the reported $2.94 in 2023. The prediction for 2025 is $6.07, $6.78 for 2026, $7.72 for 2027, and $8.54 for 2028.

What is Ligand Pharmaceuticals’s revenue forecast?

Ligand Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $163.37M for 2024, a 24.41% increase from the reported $131.31M in 2023. The forecast for 2025 is $187.13M, $225.03M for 2026, $262.6M for 2027, and $302M for 2028.

What is Ligand Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Ligand Pharmaceuticals's average annual net income forecast is $91.14M for 2024, reflecting an 74.75% increase from the reported $52.15M in 2023. The projection for 2025 is $111.34M, $120.52M for 2026, $133.8M for 2027, and $151.64M for 2028.